Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Dose Escalation and Dose Expansion of ZX-8177 Tablets in Chinese Patients With Advanced Solid Tumors

NCT07310134 is registered in ClinicalTrials.gov with Nanjing Zenshine Pharmaceuticals as lead sponsor.

NCT NCT07310134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07310134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Dose Escalation and Dose Expansion of ZX-8177 Tablets in Chinese Patients With Advanced Solid Tumors
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
December 26, 2025
Completion date
December 30, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors